How do we separate proven findings from marketing hype?
Cardiovascular research is the largest, oldest, most rigorous evidence base in nutritional and pharmaceutical medicine — and its supplement chapter teaches the field's sharpest lessons: formulation decides outcomes (REDUCE-IT's purified EPA succeeded where STRENGTH's mixed formula failed), events outrank markers, and the strongest dietary intervention in history was a cuisine, not a capsule.
The field that built evidence-based medicine teaches its reading skills best:
William Harvey demonstrates that blood circulates — pumped by the heart in a closed loop — founding modern physiology in one slender book.
James Herrick establishes that the classic 'heart attack' is coronary artery occlusion — the disease finally has its mechanism.
The cohort study that invented the risk factor — hypertension, cholesterol, smoking identified as predictors, and prevention science born.
Christiaan Barnard transfers a beating heart into Louis Washkansky — proof the organ itself could be replaced; proof, too, of how much else matters.
The Scandinavian Simvastatin Survival Study shows statins don't just lower LDL — they save lives. Cardiology's pharmaceutical century reaches full power.
Prescription EPA reduces events 25% — the supplement-class molecule proving itself at drug dosing — while SGLT2s and PCSK9s widen the prescription frontier.
POPULATION · 8,179 statin-treated adults with elevated triglycerides (135–499 mg/dL) and established or high cardiovascular risk
FINDING · Prescription purified EPA at 4 g/day reduced major cardiovascular events by 25% versus placebo.
LIMITATION · A prescription drug at a dose retail softgels don't match; hemorrhagic-stroke signal noted; the subsequent STRENGTH trial (mixed omega-3) was null — formulation questions remain open.
POPULATION · 13,078 statin-treated adults with high cardiovascular risk and elevated triglycerides
FINDING · No significant reduction in cardiovascular events with 4 g/day of a mixed EPA/DHA formulation versus placebo (corn oil).
LIMITATION · The comparator (mineral oil in the run-in) and the formulation differences from REDUCE-IT are debated — but the null stands as the boundary-drawing twin every honest omega-3 discussion must carry.
POPULATION · 420 patients with moderate-to-severe heart failure, 300 mg CoQ10 daily, 2 years
FINDING · Fewer major adverse cardiovascular events and lower cardiac death in the CoQ10 group versus placebo, as an adjunct to standard therapy.
LIMITATION · Modest sample with early termination; larger confirmatory trials awaited — an encouraging adjunct signal, honestly graded as pending confirmation.
POPULATION · 605 heart-attack survivors, ~27 months (stopped early)
FINDING · A Mediterranean-style diet rich in alpha-linolenic acid reduced cardiac death and non-fatal MI by approximately 70% versus the prudent Western diet.
LIMITATION · Stopped early for efficacy (an ethical endpoint); single region and era; the effect's size has never been replicated by any single-nutrient trial — which is itself the finding.